Loading…
Covista Inc. is projected to rise to $149.20 by 2027, a +22% move from its current price of $122.54. CVSA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $120.03 | $122.57 | $125.16 | +0.03% |
| May 30 | $119.03 | $122.60 | $126.28 | +0.05% |
| May 31 | $118.27 | $122.64 | $127.16 | +0.08% |
| Jun 1 | $117.64 | $122.67 | $127.91 | +0.10% |
| Jun 2 | $117.09 | $122.70 | $128.57 | +0.13% |
| Jun 3 | $116.60 | $122.73 | $129.18 | +0.16% |
| Jun 4 | $116.15 | $122.76 | $129.75 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $116.15 | $122.76 | $129.75 | +0.18% |
| Week 2 | $113.73 | $122.99 | $133.00 | +0.36% |
| Week 3 | $111.95 | $123.21 | $135.61 | +0.55% |
| Week 4 | $110.50 | $123.44 | $137.88 | +0.73% |
| Week 5 | $109.27 | $123.66 | $139.95 | +0.91% |
| Week 6 | $108.18 | $123.89 | $141.87 | +1.10% |
| Week 7 | $107.21 | $124.11 | $143.68 | +1.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Covista Inc. provides healthcare education in the United States, Barbados, St. Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary.
The company offers degree and non-degree programs, including bachelor's, master's, and doctoral degrees; and online certificate programs for nursing, health professions, medical, and veterinary postsecondary education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice.
The company operates Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. Covista Inc. was formerly known as Adtalem Global Education Inc.
and changed its name to Covista Inc. in February 2026. Covista was incorporated in 1987 and is headquartered in Chicago, Illinois. The asset is categorized as Consumer Defensive.
Covista Inc. trades under the symbol CVSA and is currently priced at $125.15. It holds a market capitalization of $4.26B and a market rank of 1461. The current price sits within a broader forecast path that envisions substantial upside over the coming years.
The near-term forecast anchors around 2026 with an average price of $125.15 and a range from $92.92 to $168.62, implying an ROI of 0% and a neutral sentiment. Looking further out, the averages rise toward 2030 and beyond, signaling meaningful upside into the 2030s and 2040s. In 2030, the forecast shows an average of $259.49 and a max of $363.26, with a bullish stance and an ROI of 107.3%.
By 2040, the average reaches $660.39 and the max $1,048.08, with a bullish outlook and an ROI of 427.7%. In 2050, the average is projected at $1,535.88 with a max of $2,632.89, yielding an ROI of 1127.2% and a bullish sentiment.
Overall, the price outlook suggests substantial upside potential over the long term, anchored by ongoing bullish forecasts from 2027 onward.
A major floor 24.2% below — a decisive break under it would weaken the trend.
The nearest floor, 12.2% below — buyers have tended to step in here.
The nearest ceiling, 9.1% above — a clean break opens room to run.
A major ceiling 20.3% above — clearing it would confirm fresh momentum.
Key CVSA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CVSA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $124.41 | Sell | $124.17 | Sell |
| MA 10 | $125.42 | Sell | $124.36 | Sell |
| MA 20 | $122.70 | Sell | $122.70 | Sell |
| MA 50 | $117.21 | Buy | $117.76 | Buy |
| MA 100 | $111.49 | Buy | $114.59 | Buy |
| MA 200 | $116.91 | Buy | $113.06 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.92 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -2.10 | Neutral |
| Williams %R (14) | -66.89 | Info |
| MACD (12,26,9) | -0.56 | Sell |
| ROC (12) | -8.37 | Sell |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 33.11 | Neutral |
| TRIX (15) | 0.39 | Buy |
| Awesome (5,34) | 5.26 | Buy |
| Ultimate (7,14,28) | 52.19 | Neutral |
| Momentum (10) | -5.94 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 123.55 | Sell |
| ADX (14) | 16.08 | Neutral |
| ATR (14) | 2.37 | Info |
The 30-day technical picture is bullish, with RSI(14) at 60 and moving averages indicating momentum. The SMA(50) is $116.48 and the SMA(200) is $116.88, suggesting a supportive trend near recent prices.
Key support sits at $107.63 and resistance at $133.73, shaping a near-term trading range. The 30-day price range is $108.31 to $144.61, underscoring a constructive but volatile path over the month. Annualized volatility is reported at 40%, underscoring notable price variability within the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $92.92 | $122.54 | $162.48 | 0% | Neutral | |
| $121.01 | $149.20 | $193.16 | +22% | Bullish | |
| $130.54 | $164.24 | $218.74 | +34% | Bullish | |
| $162.47 | $207.88 | $283.17 | +70% | Bullish | |
| $187.85 | $243.96 | $338.75 | +99% | Bullish | |
| $207.41 | $273.02 | $385.55 | +123% | Bullish | |
| $228.20 | $304.18 | $436.13 | +148% | Bullish | |
| $230.65 | $311.08 | $452.25 | +154% | Bullish | |
| $247.69 | $337.79 | $497.41 | +176% | Bullish | |
| $286.12 | $394.36 | $587.68 | +222% | Bullish | |
| $413.41 | $597.58 | $936.58 | +388% | Bullish | |
| $872.06 | $1,365.37 | $2,305.67 | +10.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $92.92 | $122.54 | $144.26 | +0.00% |
| June 2026 | $108.15 | $126.37 | $150.68 | +3.13% |
| July 2026 | $106.70 | $125.48 | $151.19 | -0.71% |
| August 2026 | $107.19 | $126.68 | $153.86 | +0.96% |
| September 2026 | $109.34 | $129.76 | $158.64 | +2.43% |
| October 2026 | $108.34 | $129.06 | $158.72 | -0.54% |
| November 2026 | $106.73 | $127.56 | $157.70 | -1.16% |
| December 2026 | $109.08 | $130.79 | $162.48 | +2.53% |
Click any year to see its month-by-month CVSA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CVSA to range from $92.92 to $162.48 through 2026. The $122.54 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CVSA price prediction for 2027 points to an average of $149.20 (low $121.01, high $193.16) — a potential gain of +22% on today's $122.54. Buyers look set to stay in control over this stretch.
In 2028, CVSA is projected to trade between $130.54 and $218.74, averaging $164.24 — a potential gain of +34% from today's $122.54. That is up +10% on the projected 2027 average. Momentum favours further upside here.
Covista Inc.'s 2029 outlook centres on $207.88, within a $162.47 to $283.17 range. That is up +27% on the projected 2028 average. That marks a +70% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CVSA could reach as high as $338.75, with a base case around $243.96 and support toward $187.85 — roughly +99% from $122.54. Momentum favours further upside here.
Expect CVSA to range from $207.41 to $385.55 through 2031. The $273.02 average target implies a +123% move from current prices. That is up +12% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CVSA price prediction for 2032 points to an average of $304.18 (low $228.20, high $436.13) — a potential gain of +148% on today's $122.54. Momentum favours further upside here.
In 2033, CVSA is projected to trade between $230.65 and $452.25, averaging $311.08 — a potential gain of +154% from today's $122.54. That is up +2% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Covista Inc.'s 2034 outlook centres on $337.79, within a $247.69 to $497.41 range. That is up +9% on the projected 2033 average. That marks a +176% change versus current levels. Momentum favours further upside here.
By 2035, CVSA could reach as high as $587.68, with a base case around $394.36 and support toward $286.12 — roughly +222% from $122.54. Buyers look set to stay in control over this stretch.
Expect CVSA to range from $413.41 to $936.58 through 2040. The $597.58 average target implies a +388% move from current prices. That is up +52% on the projected 2035 average. Momentum favours further upside here.
The CVSA price prediction for 2050 points to an average of $1,365.37 (low $872.06, high $2,305.67) — a potential gain of +10.1x on today's $122.54. Buyers look set to stay in control over this stretch.
Investing $1,000 in CVSA today (≈ 8.160601 CVSA) could be worth
$11,142.21
+$10,142.21 (+1014%) by 2050 · US Dollar
Based on the average projected CVSA price of $1,365.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CVSAwould be worth at today's price.
$1,000 invested in CVSA on May 27, 2025 (≈ 7.7101 CVSA) would be worth
$944.8
-$55.2 (-5.5%) today · 0.94× · US Dollar
Based on a CVSA entry price of $129.7 vs. today's $122.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $126.01 | $972.46 | -2.8% |
| 1 month ago | $112.39 | $1,090.31 | +9.0% |
| 3 months ago | $98.76 | $1,240.79 | +24.1% |
| 6 months ago | $92.56 | $1,323.9 | +32.4% |
| 1 year ago | $129.7 | $944.8 | -5.5% |
| All time (5.0y) ago | $37.63 | $3,256.44 | +225.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CVSA forecast.
Our base-case forecast reaches $250.00 around 2031.
Implied market cap at $250.00: $8.51B
The multi-year forecast shows a clear upward trajectory in the average price, with notable milestones at 2030, 2040, and 2050. For 2030 the avg is $259.49 with a max of $363.26 and an ROI of 107.3%, and sentiment remains bullish. Earlier years project steady gains from 2027 onward, with 2027’s avg $154.91 and ROI 23.8%, 2028’s avg $172.14 and ROI 37.5%, and 2029’s avg $221.34 and ROI 76.9% as catalysts for the longer run.
The 2040 forecast envisions min $451.14, avg $660.39, max $1,048.08, with ROI 427.7% and a bullish sentiment. By 2050, the min is $963.78, the avg $1,535.88, and the max $2,632.89, delivering ROI of 1127.2% and a bullish outlook. These figures are estimates and not guarantees; actual results will depend on market conditions and other factors.
There is inherent uncertainty in long-horizon forecasts, and outcomes can differ significantly from projections.
Tap a question to reveal the answer.
2030 forecast: min $198.52, avg $259.49, max $363.26; ROI 107.3%; sentiment BULLISH.
Forecasts show a bullish sentiment from 2027 onward with rising averages (e.g., 2027 avg $154.91; 2030 avg $259.49; 2040 avg $660.39; 2050 avg $1,535.88) and substantial ROIs (e.g., 23.8% in 2027, 107.3% in 2030, 427.7% in 2040, 1127.2% in 2050). These are estimates, not guarantees.
Yes. The forecast max reaches $1,048.08 by 2040 and $2,632.89 by 2050, with the 2040 max exceeding $1,000.
Current price: $125.15. Market cap: $4.26B.
RSI(14) 60; SMA(50) $116.48; SMA(200) $116.88; support $107.63; resistance $133.73; 30-day range $108.31-$144.61; sentiment BULLISH; annualized volatility 40%.
Covista Inc. Community Discussion
0Share your Covista Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.